Cargando…
Development of the Pulmonary Arterial Hypertension-Symptoms and Impact (PAH-SYMPACT®) questionnaire: a new patient-reported outcome instrument for PAH
BACKGROUND: Regulators and clinical experts increasingly recognize the importance of incorporating patient-reported outcomes (PROs) in clinical studies of therapies for pulmonary arterial hypertension (PAH). No PAH-specific instruments have been developed to date in accordance with the 2009 FDA guid...
Autores principales: | McCollister, Deborah, Shaffer, Shannon, Badesch, David B., Filusch, Arthur, Hunsche, Elke, Schüler, René, Wiklund, Ingela, Peacock, Andrew |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4908719/ https://www.ncbi.nlm.nih.gov/pubmed/27301413 http://dx.doi.org/10.1186/s12931-016-0388-6 |
Ejemplares similares
-
Symptoms, impacts, and suitability of the Pulmonary Arterial Hypertension-Symptoms and Impact (PAH-SYMPACT™) questionnaire in patients with sarcoidosis-associated pulmonary hypertension (SAPH): a qualitative interview study
por: Currie, Brooke M., et al.
Publicado: (2021) -
Symptoms, impacts, and suitability of the Pulmonary Arterial Hypertension – Symptoms and Impact (PAH-SYMPACT™) questionnaire in patients with chronic thromboembolic pulmonary hypertension (CTEPH): a qualitative interview study
por: Currie, Brooke, et al.
Publicado: (2021) -
INSPIRE: Safety and tolerability of inhaled Yutrepia (treprostinil) in pulmonary arterial hypertension (PAH)
por: Hill, Nicholas S., et al.
Publicado: (2022) -
Biodegradation of Mixed PAHs by PAH-Degrading Endophytic Bacteria
por: Zhu, Xuezhu, et al.
Publicado: (2016) -
PAH Exposure
por: Fowler, Paul A., et al.
Publicado: (2009)